SignatureCare Emergency Center Now Administering Eli Lilly’s Bamlanivimab and Etesevimab Monoclonal Antibody Treatment for COVID-19
SignatureCare Emergency Center has been approved to administer Eli Lilly’s Bamlanivimab (LY-CoV555) and Etesevimab COVID-19 treatment to patients through its network of 24-hour emergency centers located in Texas.
“We are happy to offer this to our patients throughout Texas. Bamlanivimab (LY-CoV555) and Etesevimab have proven through studies to be effective in reducing the severity of COVID-19 symptoms and we believe it will be very helpful to our patients who receive the treatment,” he said.
Eli Lilly recently announced that Bamlanivimab (LY-CoV555) was able to substantially reduce symptomatic disease among residents and staff of long-term facilities during its recently completed study.
Dr. Hannan said that although no preregistration is required before receiving the treatment, all patients will be evaluated by the attending ER physician prior to receiving the treatment.
“This treatment is available now and no preregistration is required to receive the treatment through our emergency centers. Simply walk into the ER and our board-certified physicians will evaluate you to ensure you can receive the treatment. It will then be administered if you are eligible,” Dr. Hannan said.